Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:IKT NASDAQ:OLMA NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$32.48$29.07$13.09▼$35.66$889.70M0.87353,758 shs612,756 shsIKTInhibikase Therapeutics$1.83$1.77$1.33▼$2.26$241.62M0.92559,336 shs1.48 million shsOLMAOlema Pharmaceuticals$9.51$13.39$4.02▼$36.26$830.67M1.981.49 million shs2.87 million shsTBPHTheravance Biopharma$16.58$16.50$10.44▼$21.03$854.75M0.17380,216 shs952,850 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals-0.85%+1.15%-1.25%+45.52%+137.08%IKTInhibikase Therapeutics+8.93%+9.58%+16.56%+1.67%+182,999,900.00%OLMAOlema Pharmaceuticals+0.74%-2.46%-27.40%-32.46%+131.95%TBPHTheravance Biopharma-0.78%+0.55%+2.03%+15.70%+56.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$32.48$29.07$13.09▼$35.66$889.70M0.87353,758 shs612,756 shsIKTInhibikase Therapeutics$1.83$1.77$1.33▼$2.26$241.62M0.92559,336 shs1.48 million shsOLMAOlema Pharmaceuticals$9.51$13.39$4.02▼$36.26$830.67M1.981.49 million shs2.87 million shsTBPHTheravance Biopharma$16.58$16.50$10.44▼$21.03$854.75M0.17380,216 shs952,850 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals-0.85%+1.15%-1.25%+45.52%+137.08%IKTInhibikase Therapeutics+8.93%+9.58%+16.56%+1.67%+182,999,900.00%OLMAOlema Pharmaceuticals+0.74%-2.46%-27.40%-32.46%+131.95%TBPHTheravance Biopharma-0.78%+0.55%+2.03%+15.70%+56.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 2.40Hold$41.0026.23% UpsideIKTInhibikase Therapeutics 3.11Buy$5.40195.08% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10363.72% UpsideTBPHTheravance Biopharma 2.29Hold$21.4029.07% UpsideCurrent Analyst Ratings BreakdownLatest IKT, ETON, OLMA, and TBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026IKTInhibikase Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/8/2026TBPHTheravance Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/27/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/8/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$79.95M11.13$0.01 per share6,320.42$0.98 per share33.14IKTInhibikase Therapeutics$260K929.29N/AN/A$2.30 per share0.80OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ATBPHTheravance Biopharma$107.46M7.95N/AN/A$5.86 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$4.60M-$0.07N/A17.01N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.43N/AN/AN/AN/A-41.31%-38.98%N/AOLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.207.5461.41N/A104.34%18.84%10.94%8/11/2026 (Estimated)Latest IKT, ETON, OLMA, and TBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/12/2026Q1 2026IKTInhibikase Therapeutics-$0.10-$0.10N/A-$0.10N/AN/A5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 million3/31/2026Q4 2025TBPHTheravance BiopharmaN/A-$0.10N/A-$0.10N/A$17.70 million3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals0.621.210.88IKTInhibikase TherapeuticsN/A30.1430.14OLMAOlema Pharmaceuticals0.0110.8810.88TBPHTheravance BiopharmaN/A13.1413.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%IKTInhibikase Therapeutics3.81%OLMAOlema Pharmaceuticals91.78%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.49%IKTInhibikase Therapeutics7.10%OLMAOlema Pharmaceuticals12.56%TBPHTheravance Biopharma7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2027.39 million22.88 millionOptionableIKTInhibikase Therapeutics6132.03 million122.66 millionN/AOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableTBPHTheravance Biopharma11051.55 million47.61 millionOptionableIKT, ETON, OLMA, and TBPH HeadlinesRecent News About These CompaniesTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by BrokeragesJune 19 at 4:07 AM | americanbankingnews.comInsider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares of StockJune 18 at 8:13 AM | insidertrades.comTBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline HurdleMay 8, 2026 | zacks.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockMay 7, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7, 2026 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comLaughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH)April 25, 2026 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance ...April 21, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 21, 2026 | globenewswire.comB. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14April 20, 2026 | insidermonkey.com8 Most Undervalued Biotech Stocks to Buy Right NowApril 18, 2026 | insidermonkey.comTheravance Stock Declines Around 17% in Three Months: Here's WhyApril 16, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 16, 2026 | prnewswire.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockApril 15, 2026 | zacks.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 15, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH)April 10, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 9, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Qualcomm's TikTok AI Chip Deal Rewrites the RulesBy Jeffrey Neal Johnson | May 27, 2026IKT, ETON, OLMA, and TBPH Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$32.48 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$32.00 -0.48 (-1.48%) As of 06/18/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Inhibikase Therapeutics NASDAQ:IKT$1.83 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.82 -0.01 (-0.27%) As of 06/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Olema Pharmaceuticals NASDAQ:OLMA$9.51 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$9.59 +0.08 (+0.79%) As of 06/18/2026 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Theravance Biopharma NASDAQ:TBPH$16.58 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$16.58 +0.01 (+0.03%) As of 06/18/2026 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
